TY - JOUR T1 - Cannabidiol reduced frequency of convulsive seizures in drug resistant Dravet syndrome JF - Archives of disease in childhood - Education & practice edition JO - Arch Dis Child Educ Pract Ed SP - 278 LP - 279 DO - 10.1136/archdischild-2017-313700 VL - 103 IS - 5 AU - Yasmin Moore AU - Robert Robinson Y1 - 2018/10/01 UR - http://ep.bmj.com/content/103/5/278.abstract N2 - Design: Multinational double-blinded placebo-controlled trial.1 Patients randomised in 1:1 ratio to receive cannabidiol or placebo, in addition to stable antiepileptic treatment regime. Setting: Twenty-three centres in Europe and USA. Patients: Patients aged 2 years to 18 years with established diagnosis of Dravet syndrome having at least four convulsive seizures during the 28-day baseline period despite regular antiepileptic medication. Intervention: Adjunctive cannabidiol or placebo oral solution at 20 mg per kilogram of body weight per day. Primary outcome: Percentage change in median frequency of convulsive seizures per month. Follow-up period: Outcome measured over a 14-week treatment period in comparison to a 4-week baseline period. Patient follow-up: One hundred and eight (90%) completed the trial: 85% (52/61) in the … ER -